Ep17 ep30

Manufactured by Agilent Technologies

Sourced in Australia

The EP17/EP30 is a piece of lab equipment produced by Agilent Technologies. It is designed to perform specific laboratory functions, but a detailed and unbiased description cannot be provided while maintaining conciseness.

Automatically generated - may contain errors

Lab products found in correlation

Mouse e cadherin, by BD (1 mentions) Cd44 pe, by Miltenyi Biotec (1 mentions) Sca1 pe, by Miltenyi Biotec (1 mentions) Epcam apc, by Thermo Fisher Scientific (1 mentions) Cd24 apc, by Miltenyi Biotec (1 mentions) Ab5694, by Abcam (1 mentions) Ab74666, by Abcam (1 mentions) M0851, by Agilent Technologies (1 mentions) M0760, by Agilent Technologies (1 mentions) E cadherin nch 38, by Agilent Technologies (1 mentions) Histogel, by StatLab (1 mentions) Chromogranin a, by Immunostar (1 mentions) β catenin 1, by Agilent Technologies (1 mentions) Ab92547, by Abcam (1 mentions)

3 protocols using ep17 ep30

Comprehensive Antibody Panel for Cellular Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

The antibodies used for Western blotting (WB), immunofluorescence (IF), immunohistochemistry (IHC) and flow cytometry (FC) were as follows: human and mouse Annexin A1 (WB, IF), mouse mAb clone EH17a (Santa Cruz Biotechnology, Dallas, TX, USA). Human Annexin A1 (IHC), mouse mAb clone MRQ-3 (Cell Marque, Sigma Aldrich). Mouse E-cadherin (IF, IHC), mouse mAb clone E-cad/36 (BD Transduction Laboratories, BD Biosciences, Scoresby, Vic., Australia). Mouse CD24 (FACS), CD24-PE-Vio770 or CD24-APC, rat mAb clone M1/69 (Miltenyi Biotec, Macquarie Park, NSW, Australia), mouse CD44 (FACS), CD44-PE, rat mAb clone IM7.8.1 (Miltenyi Biotec), mouse Epcam/CD326 (FACS), Epcam-APC, rat mAb clone G8.8 (eBioscience, Invitrogen, Thermo Fisher Scientific, Scoresby, Vic., Australia). Mouse cytokeratin 14 (IHC), mouse mAb clone LL002 (Abcam, Melbourne, Vic, Australia). Mouse pan-cytokeratin (recognizing type II cytokeratins 1, 5, 6, and 8) (IHC), mouse mAb clone PCK-26 (Sigma-Aldrich). Mouse cytokeratins 8–18 (IHC), rabbit mAb clones EP17/EP30 (Dako, Leica Microsystems, Macquarie Park, NSW, Australia). Mouse alpha smooth muscle actin (αSma) (IF), rabbit pAb ab5694 (Abcam). Mouse Sca1 (Ly6a) (FACS), Sca1-PE, rat mAb clone D7 (Miltenyi Biotec). Mouse vimentin (IHC), rabbit pAb R28 (Cell Signaling Technology, Danvers, MA, USA).

Johnstone C.N., Tu Y., Langenbach S., Baloyan D., Pattison A.D., Lock P., Britt K.L., Lehmann B.D., Beilharz T.H., Ernst M., Anderson R.L, & Stewart A.G. (2021). Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer. Cancers, 13(5), 1154.

+ Open protocol

+ Expand

Histological Characterization of Intestinal Tissue

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Intestinal tissue was fixed overnight in 10% neutral buffered formalin and stored in 70% ethanol until further histologic processing. Intestinal cultures were fixed in 10% buffered formalin for 5 minutes then resuspended in 30 μL preheated Histogel (American MasterTech) and stored in ethanol as above. Specimens were embedded in paraffin and sectioned at 3 μm thickness. Hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) were performed per standard protocol (Lahar et al. 2011 (link); Jabaji et al. 2013 (link)). Staining was done using antibodies against CD10 (56C6, Dako, Carpinteria, CA), lysozyme (ab74666, Abcam, Cambridge, MA), chromogranin A (20086, Immunostar, Hudson, WI) (Gonzalez et al. 2013 (link)), villin (1D2C3, Dako), E-cadherin (NCH-38, Dako), β-catenin (β-Catenin-1, Dako), p120-catenin (98, Ventana, Tucson, AZ), and cytokeratin 8 and 18 (EP17/EP30, Dako). Goblet cells were identified with the periodic acid-Schiff (PAS) stain (Brown et al. 1988 (link)). Porcine ISEMFs were plated in 0.95 cm² culture wells, fixed as above, and stained with antibodies against α-smooth muscle actin (α-SMA, M0851, Dako), desmin (M0760, Dako), and vimentin (ab92547, Abcam). For immunofluorescent stains, conjugated goat secondary antibody (Invitrogen) was added at 1:200 dilution and nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen).

Khalil H.A., Lei N.Y., Brinkley G., Scott A., Wang J., Kar U.K., Jabaji Z.B., Lewis M., Martín M.G., Dunn J.C, & Stelzner M.G. (2016). A Novel Culture System for Adult Porcine Intestinal Crypts. Cell and tissue research, 365(1), 123-134.

+ Open protocol

+ Expand

Tumour Budding Assessment in Colorectal Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

A tumour bud is defined as a single tumour cell or a cell cluster of up to four tumour cells which develops from neoplastic glands. Tb was analysed along the invasive parts of the tumour using the hotspot method, which is considered to be the most useful method for assessing Tb in colorectal cancer. 9 Initially, the invasive front of the tumour was screened using low magnification to find the areas with most Tb. For this purpose, cytokeratin 8-18 [monoclonal, clone EP17/EP30, Dako] immunohistochemistry was helpful in some challenging cases [i.e. glandular fragmentation, strong peritumoral inflammation] to allow a better visualisation of Tb-rich areas. Tb was assessed from several H&E areas, and the single field with the most budding was used for quantitation. The number of buds was counted in all cancers on H&E staining from a single field of view using ×200 total magnification [the hotspot method]. Following the International Tumour Budding Consensus Conference [ITBCC] group recommendation for colorectal cancer, we used a three-tier system: low budding [Tb1]: 0-4 buds; intermediate budding [Tb2]: 5-9 buds; and high budding [Tb3]: 10 or more buds. 9

Arpa G., Grillo F., Giuffrida P., Nesi G., Klersy C., Mescoli C., Lenti M.V., Lobascio G., Martino M., Latella G., Malvi D., Macciomei M.C., Fociani P., Villanacci V., Rizzo A., Ferrero S., Sessa F., Orlandi A., Monteleone G., Biancone L., Cantoro L., Tonelli F., Ciardi A., Poggioli G., Rizzello F., Ardizzone S., Sampietro G., Solina G., Oreggia B., Papi C., D'Incà R., Vecchi M., Caprioli F., Caronna R., D'Errico A., Fiocca R., Rugge M., Corazza G.R., Luinetti O., Paulli M., Solcia E., Di Sabatino A, & Vanoli A. (2020). Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker Analysis. Journal of Crohn's & colitis, 14(3).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!